Polycystic ovary syndrome: Implications of measurement of plasma aldosterone, renin activity and progesterone

Steroids

Volumn 77, Issue 6, 2012, Pages 655-658

  Armanini, Decio ^a   Bordin, Luciana ^a   Donà, Gabriella ^a   Sabbadin, Chiara ^a   Bakdounes, Leila ^a   Ragazzi, Eugenio ^a   Giorgino, Francesco L ^b   Fiore, Cristina ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b AGEO   (Italy)

Author keywords

Aldosterone; Aldosterone PRA; Cardiovascular risk; Plasma renin activity (PRA); Polycystic ovary syndrome; Progesterone

Indexed keywords

ALDOSTERONE; PROGESTERONE; RENIN;

ADULT; ALDOSTERONE BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MEAN ARTERIAL PRESSURE; OVARY POLYCYSTIC DISEASE; PLASMA RENIN ACTIVITY; PROGESTERONE BLOOD LEVEL;

ADULT; ALDOSTERONE; CASE-CONTROL STUDIES; FEMALE; HUMANS; LUTEAL PHASE; POLYCYSTIC OVARY SYNDROME; PROGESTERONE; RENIN; YOUNG ADULT;

EID: 84859843863     PISSN: 0039128X     EISSN: 18785867     Source Type: Journal    
DOI: 10.1016/j.steroids.2012.02.010     Document Type: Article

References (27)

1. Azziz R, Marin C, Hoq L, Badamgarav E, Song P. Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span. J Clin Endocrinol Metab 2005;90:4650-8. (Pubitemid 41159355)
2. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41-7.
3. Orio Jr F, Palomba S, Spinelli L, Cascella T, Tauchmanovà L, Zullo F, et al. The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study. J Clin Endocrinol Metab 2004;89:3696-701. (Pubitemid 39071458)
4. Pitt B, Zannad F, Remme WJ, Kody R, Castaigne A, Perez A, Palenski J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med 1999;341:709-17. (Pubitemid 29407370)
5. Pitt B, Remme W, Zanad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21. (Pubitemid 36384098)
6. Funder JW. Reconsidering the roles of the mineralocorticoid receptor. Hypertension 2009;53:286-90.
7. Armanini D, Fiore C. Some considerations about evolution of idiopathic primary aldosteronis. J Endocrinol Invest 2009;32:623-5.
8. Cascella T, Palomba S, Tauchmanovà L, Manguso F, Di Biase S, Labella D, et al. Serum aldosterone concentration and cardiovascular risk in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2006;91:4395-400. (Pubitemid 44833415)
9. Chidambaram M, Duncan JA, Lai VS, Cattran DC, Floras JS, Scholey JW, et al. Variation in the renin angiotensin system throughout the normal menstrual cycle. J Am Soc Nephrol 2002;13:446-52. (Pubitemid 34106287)
10. Fommei E, Ghione S, Ripoli A, Maffei S, Di Cecco P, Iervasi A, et al. The ovarian cycle as a factor of variability in the laboratory screening for primary aldosteronism in women. J Hum Hypertens 2009;23:130-5.
11. Chen MJ, Yang WS, Yang JH, Chen CL, Ho HN, Yang YS. Relationship between androgen levels and blood pressure in young women with polycystic ovary syndrome. Hypertension 2007;49:1442-7.
12. Armanini D, Pellati D, Fiore C. Polycystic ovary syndrome: implications of corticotropin in the regulation of blood pressure, aldosterone, and androgen secretion. Hypertension 2007;50:e24. (Pubitemid 47205810)
13. Draper N, Walker EA, Bujalska IJ, Tomlinson JW, Chalder SM, Arlt W, et al. Mutations in the genes encoding 11beta-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase deficiency. Nat Genet 2003;34:434-9. (Pubitemid 36935337)
14. Rodin A, Thakkar H, Taylor N, Clayton R. Hyperandrogenism in polycystic ovary syndrome. Evidence of dysregulation of 11 beta-hydroxysteroid dehydrogenase. N Engl J Med 1994;330:460-5. (Pubitemid 24058934)
15. Lavery GG, Walker EA, Tiganescu A, Ride JP, Shackleton CH, Tomlinson JW, et al. Steroid biomarkers and genetic studies reveal inactivating mutations in hexose-6-phosphate dehydrogenase in patients with cortisone reductase deficiency. J Clin Endocrinol Metab 2008;93:3827-32.
16. Quinkler M, Meyer B, Bumke-Vogt C, Grossmann C, Gruber U, Oelkers W, et al. Agonistic and antagonistic properties of progesterone metabolites at the human mineralocorticoid receptor. Eur J Endocrinol 2002;146:789-99.
17. Szmuilowicz ED, Adler GK, Williams JS, Green DE, Yao TM, Hopkins PN, et al. Relationship between aldosterone and progesterone in the human menstrual cycle. J Clin Endocrinol Metab 2006;91:3981-7. (Pubitemid 44536873)
18. Willis DS, Watson H, Mason HD, Galea R, Brincat M, Franks S. Premature response to luteinizing hormone of granulosa cells from anovulatory women with polycystic ovary syndrome: relevance to mechanism of ovulation. J Clin Endocrinol Metab 1998;83:3984-91. (Pubitemid 28513584)
19. Qublan H, Amarin Z, Nawasreh M, Diab F, Malkawi S, Al-Ahmad N, et al. Luteinized unruptured follicle syndrome: incidence and recurrence rate in infertile women with unexplained infertility undergoing intrauterine insemination. Hum Reprod 2006;21:2110-3. (Pubitemid 44288090)
20. Savaris RF, Groll JM, Young SL, DeMayo FJ, Jeong JW, Hamilton AE, et al. Progesterone resistance in PCOS endometrium: a microarray analysis in clomiphene citrate-treated and artificial menstrual cycle. J Clin Endocrinol Metab 2011;96:1737-46.
21. Check JH. Cryptic infertility and therapeutic options. Clin Exp Obstet Gynecol 2001;28:205-11. (Pubitemid 34154990)
22. Franks S, Gharani N, McCarthy M. Genetic abnormalities in polycystic ovary syndrome. Ann Endocrinol 1999;60:131-3. (Pubitemid 29359904)
23. Strauss 3rd JF. Some new thoughts on the pathophysiology and genetics of polycystic ovary syndrome. Ann NY Acad Sci 2003;997:42-8.
24. Oelkers W, Foidart JM, Dombrovicz N, Welter A, Heithecker R. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab 1995;80:1816-21.
25. Armanini D, Castello R, Scaroni C, Bonanni G, Faccini G, Pellati D, et al. Treatment of polycystic ovary syndrome with spironolactone plus licorice. Eur J Obstet Gynecol Reprod Biol 2007;131:61-7. (Pubitemid 46283205)
26. Armanini D, Fiore C, Pellati D. Spontaneous resolution of idiopathic aldosteronism after long-term treatment with potassium canrenoate. Hypertension 2007;50:e69-70. (Pubitemid 47442748)
27. Armanini D, Scaroni C, Mattarello MJ, Fiore C, Albiger N, Sartorato P. Idiopathic primary hyperaldosteronism: normalization of plasma aldosterone after one month withdrawal of long-term therapy with aldosterone-receptor antagonist potassium canrenoate. J Endocrinol Invest 2005;28:236-40. (Pubitemid 43162771)